8th Annual Outsourcing in Clinical Trials East Asia 2024

The leading clinical outsourcing conference in East Asia helping you enhance your end-to-end clinical strategy

3 - 4

December

2024
  • Seoul, South Korea
  • Ticketed
  • Why attend?
  • Agenda
  • 2023 Speakers
  • Plan Your Visit
  • Event Gallery
  • Sponsors
  • Media Centre
  • Why partner?
  • Contact Us
close

Why attend?

Agenda

  • 3 Dec 2024
  • 4 Dec 2024
Expand All

Streams

Stream one

Outsourcing in Clinical Trials East Asia

8:30 AM

Registration and refreshments

8:50 AM

Chairperson’s opening remarks

9 AM

KEY NOTE Choosing the right CRO: Essential considerations for a successful partnership

• Recognizing common misconceptions when selecting a CRO that may not align with your values and trial requirements
• Determining the essential resources and capabilities that the CRO must possess to ensure the success of your trial
• Managing that all important budget to avoiding overspending

Speakers

Sueun Song
Division Head of Clinical Development, Celltrion

9:30 AM

Reducing drug waste – how Technology makes clinical supply more efficient

• Drug waste in clinical trials: why is it a big deal?
• Identifying the main drivers of waste
• How technology enables more accurate and sustainable supply planning, leading to costs and drug waste reduction
• Illustration through case studies

Speakers

Marine du Jardin
APAC Regional Manager & Partnership Lead, N-SIDE
Amaury Jeandrain
Vice President of Strategy, N-SIDE

10 AM

Master protocols in biotech: Design and implementation

• Concept of master protocols
• FDA perspectives on mater protocols
• Operation of complex study design
• Examples of mater protocols

Speakers

Nari Yun
Executive Director, Clinical Development, GI Innovation Inc.

10:30 AM

The Future of Clinical Trials: Clinical Innovation Solutions Utilizing of Artificial Intelligence (AI)

• The key trends in the clinical trials landscape
• How to do CROs use AI in clinical trials
• Real-world cases of AI and CRO

Speakers

YOONI KIM
Vice President Clinical Services, Novotech
Daniela Caiazza
Senior Director Clinical Services and Innovation, Novotech

11 AM

Morning refreshments and networking

11:30 AM

The challenges and benefits of Risk-Based Monitoring models in clinical trials

• Understanding the challenges and barriers in implementing risk-based monitoring models in clinical trials
• Choosing the correct RBM strategy to apply to your trial to reduce the time to approval for INDs
• Discussing the benefits of risk-based monitoring in optimizing resource allocation, such as reducing on-site monitoring visits

Speakers

Sol Han
Chief Medical Officer, Cyrus Therapeutics

12 PM

Reserved for the Event Partner

12:30 PM

Vendor management: Aligning vendors and sponsors for successful trial delivery

• Addressing the challenges associated with working with multiple vendors instead of a single CRO and offering insights on how to align goals and streamline operations effectively
• Emphasizing the importance of clear and consistent communication, as well as fostering strong relationships with vendors and CROs
• Exploring the optimal level of oversight and sponsor involvement in the CRO partnership

Speakers

Eunsun Lee
Director, TiumBio

1 PM

Lunch and networking

2 PM

CASE STUDY Successful Clinical Trial in Oncology; Dose Optimization in Oncology Drug Development

• Ensuring strict adherence to the inclusion and exclusion criteria is vital to select the appropriate patient population for your oncology trial
• Carefully selecting clinically meaningful and relevant endpoints is crucial in oncology trials
Compliance with regulatory and ethical considerations in oncology Trials: Upholding Good Clinical Practice (GCP) Guidelines

Speakers

Young Su (Bobby) Noh
Director, Head of Clinical Science, Hanmi Pharm

2:30 PM

Reserved for the ViroClinics

3 PM

Development of Clinical Grade iPSC-Derived NK cells for Cancer Immunotherapy

• Utilizing iPSC-derived NK cells as a promising avenue in cancer immunotherapy
• Harnessing the potential of iPSC technology for personalized and effective treatments
• Offering a versatile and targeted approach to combating various cancer types with enhanced therapeutic efficacy

Speakers

Shin-Il Kim
Chief Scientific Officer, THERABEST

3:30 PM

Afternoon refreshments and networking

4 PM

Addressing Management Risks and Challenges in Implementing Decentralized Clinical Trials (DCT) and Digital Tools in Global Clinical Trials

• Introduction of DCT elements and examples of digital tools in global clinical trials
• Addressing potential operation and management Risks

Speakers

Tina Sun
Study & Site Operations Country Head (Taiwan)- Novartis

4:30 PM

KEYNOTE REUNION DEBATE: How did we do?

This is an opportunity to reflect on the advancements, challenges, and new developments in the field of clinical trials.

 

 

• The impact of recent social & political events- How has the industry adapted to ensure continuity and patient safety? What innovative strategies have been implemented, and how have they shaped the future of clinical trials?
• Regulatory landscape- latest updates and changes in regulations governing clinical trials. How have these changes impacted trial design, conduct, and data reporting?
• Digital transformation- What are the latest trends in digital solutions, and how are they being integrated into clinical trial operations?

Speakers

Moon Hwan Kim
Chief Technology Officer, Veraverse
SANGHO MA
Chief Development Officer, Bilix
Tina Sun
Study & Site Operations Country Head (Taiwan)- Novartis

5:15 PM

Chairperson’s closing remarks

Streams

Stream one

Outsourcing in Clinical Trials East Asia

8:15 AM

Registration and refreshments

8:50 AM

Chairperson’s opening remarks

9 AM

Case Study: Nanomedicine clinical trials conducted by a Korean biotech in Australia

• Introduction to Nanomedicine and its Significance in Clinical Trials
• Rationale for Choosing Australia as the Clinical Trial Location
• Overcoming Challenges: Logistics, Communication, and Collaboration
• Lessons Learned and Recommendations for Future Cross-Border Trials

Speakers

SANGHO MA
Chief Development Officer, Bilix

10 AM

Outsourcing of Pharmacovigilance in Korea: An Example and Experience

• Understanding the current status of pharmacovigilance outsourcing trends in the Korean pharmaceutical sector
• Detailing the criteria and considerations for selecting the right outsourcing partner for pharmacovigilance
• Sharing methodologies to assess and manage potential risks associated with outsourcing

Speakers

Juhee Jeon
PV Manager, PV Team Leader, HANA Pharm.

11 AM

Morning refreshments and networking

11:30 AM

Patient Safety and Evaluation in Clinical Operations: Enhancing Safety and Quality in Clinical Research

• Exploring strategies Including Risk Assessment, Quality Management, Adverse Event Reporting, Safety Monitoring, and Patient-Centered Approaches
• Aim for Improved Clinical Trial Outcomes and better patient care

Speakers

Jessica Thongcharen
DIRECTOR, GLOBAL PATIENT SAFETY & EVALUATION – CLINICAL OPERATIONS

11:30 AM

PANEL DISCUSSION: Clinical Trials in Asia: Insights and Perspectives ‘Unlocking efficient strategies to manage multiple countries’ regulations for global trials to increase productivity and achieve high quality results from all operation sites

• Opportunities and challenges in conducting clinical trials in Asia- Advantages and considerations for choosing Asian countries as trial sites
• Regulatory landscape- Understanding the unique regulatory frameworks and requirements for clinical trials
• Collaboration and partnership opportunities- Collaboration models with local research organizations, hospitals, and academic institutions to leverage

Speakers

Moon Hwan Kim
Chief Technology Officer, Veraverse
Jessica Thongcharen
DIRECTOR, GLOBAL PATIENT SAFETY & EVALUATION – CLINICAL OPERATIONS
Guoqing Yang
Clinical compliance and quality assurance director, Shanghai Henlius Biotech

12:45 PM

Lunch and networking

1:45 PM

Prize Draw Join us for a chance to win one of our prizes, including Apple products

2 PM

Speaker Hosted Roundtables

Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

Roundtable session lasts for 45 minutes, and we’ll have a 45min wrap up session
ROUNDTABLE 1: Establishing strategies for vendor management and oversight to strengthen collaboration

Seoyeon Hyun, Clinical Development Director, ILIAS Biologics

ROUNDTABLE 2: Navigating global supply chain hurdles when shipping cold chain supplies oversea

Guoqing Yang, Executive Director, Clinical Quality Assurance, Shanghai Henlius Biotech

ROUNDTABLE 3: Decentralized clinical trials and technology

Moon Hwan Kim, Chief Technology Officer, Veraverse

 

 

3:30 PM

Chairperson’s closing remarks

10:30 AM

Leveraging Real World Evidence/Data for enhanced study design and execution

• Unveiling how RWE can be effectively utilized to identify and locate patients, expediting the recruitment process
• Highlighting the significance of RWE in protocol modelling
• Exploring competitive intelligence and landscape assessments to identify investigators with the capacity for your study

Speakers

Taegyun Park
Head of R&D, Qratis

2023 Speakers

Select a speaker to learn more

Back
Moon Hwan Kim
Chief Technology Officer, Veraverse

Session Details:

KEYNOTE REUNION DEBATE: How did we do?

2023-12-05, 4:30 PM

Session Details:

PANEL DISCUSSION: Clinical Trials in Asia: Insights and Perspectives ‘Unlocking efficient strategies to manage multiple countries’ regulations for global trials to increase productivity and achieve high quality results from all operation sites

2023-12-06, 11:30 AM

View In Agenda
Next speaker
Back
Jaehyun Park
Managing Director, Animuscure

August, 2018 ~ Adjunct Professor, College of Pharmacy, Sunchon National University

January, 2023 ~ Managing Director, AniMusCure Inc., Suwon, Korea

< EDUCATION >

B.S. Pharmacy, College of Pharmacy, Sungkyunkwan University, Korea

M.S. Biochemistry, College of Pharmacy, Sungkyunkwan University, Korea

Ph.D. Biochemistry, College of Pharmacy, Sungkyunkwan University, Korea

< PROFESSIONAL EXPERIENCES >

- Assistant Manager, Kolon Pharmaceuticals Inc.

- Assistant Manager, Kolon Life Science, Ins., Seoul, Korea

- Research Fellow, Daewoong Pharmaceutical Co.

- Deputy Director, DanDi Bioscience, Inc.,

- Director, Selecxine, Inc.

- Managing Director, Genencell Co., Ltd.

Next speaker
Back
Tina Sun
Study & Site Operations Country Head (Taiwan)- Novartis

Education:

  • National Taiwan University, Pharmacy (1993-1997)
  • National Taiwan University of Science and Technology, EMBA (2022-2023)

Working experience:

Current: Novartis SSO country head試驗監測部長/臨床研究部/全球藥物研發中心

  • Head of Clinical Operations, Taiwan & Hong Kong, Eli Lilly Taiwan (2010-2019)
  • Trial Monitoring (TMO) Country Head, Novartis Taiwan (2019-2023)
  • Study & Site Operations (SSO) Country Head, Novartis Taiwan (2023~)

External Engagement:

  • TransCelerate Taiwan Country Lead (2013~)
  • Taiwan Clinical Research Association (TCRA) ex-president (2014); Executive Director (2015~)

Tina has over 20 years of experience in clinical operations. She was Head of Clinical Operations to manage Taiwan & Hong Kong for 10 years when at Eli Lilly before joined Novartis as the TMO Country Head in Taiwan, 2019. Tina is interested in external engagement activities through her journey in clinical operations, she is Transcelerate Taiwan Country lead since 2013 and was ex-president (2014) and current executive director in Taiwan Clinical Research Association

Session Details:

Addressing Management Risks and Challenges in Implementing Decentralized Clinical Trials (DCT) and Digital Tools in Global Clinical Trials

2023-12-05, 4:00 PM

Session Details:

KEYNOTE REUNION DEBATE: How did we do?

2023-12-05, 4:30 PM

View In Agenda
Next speaker
Back
SANGHO MA
Chief Development Officer, Bilix

Sang Ho, MA is Vice President, at the Bilix which Biotech in south korea. He is expert member of MFDS (Ministry of Food & Drug Safety) & judge member of KDDF. (Korea Drug Development Fund) His current research area is acute & chronic inflammatory disease & drug delivery system. Pursuing this R&D agenda he has recently been working with global CRO & CMO. He wrote his Ph.D. on the specific chemistry for drug development at the Graduate Institute in south korea. Since 2006, he has been a senior researcher of JW Pharma & GC Pharma for more than 14 years. And he joined Bilix in 2019 and is currently the head of the research institute and Chief Development Officer.

Session Details:

KEYNOTE REUNION DEBATE: How did we do?

2023-12-05, 4:30 PM

Session Details:

Case Study: Nanomedicine clinical trials conducted by a Korean biotech in Australia

2023-12-06, 9:00 AM

View In Agenda
Next speaker
Back
Guoqing Yang
Clinical compliance and quality assurance director, Shanghai Henlius Biotech

Session Details:

PANEL DISCUSSION: Clinical Trials in Asia: Insights and Perspectives ‘Unlocking efficient strategies to manage multiple countries’ regulations for global trials to increase productivity and achieve high quality results from all operation sites

2023-12-06, 11:30 AM

View In Agenda
Next speaker
Back
Sol Han
Chief Medical Officer, Cyrus Therapeutics

Session Details:

The challenges and benefits of Risk-Based Monitoring models in clinical trials

2023-12-05, 11:30 AM

View In Agenda
Next speaker
Back
Nari Yun
Executive Director, Clinical Development, GI Innovation Inc.

Dr. Yun began her career at Hanmi Pharmaceuticals, took the major role in managing all activities associated with the clinical development programs for key assets including long-acting insulin, GLP-1 agonist and GLP-1/GCG dual agonist. She engaged in full courses of drug development, ranging from CDP/TPP development, clinical strategy formulation and operations, licensing out and co-development with partners. She also served as a strategic consultant in IQVIA, worked on consulting projects for key business decisions, including business planning and strategy formulation, asset valuation and pricing & reimbursement strategy for various drugs etc.

In September 2019, Dr. Yun joined to GI Innovation and has led clinical collaboration agreement of company’s immunooncology asset with global pharmaceutical companies, including MSD and AstraZeneca. She is now serving as a head of clinical development.

Dr. Yun is a registered pharmacist in Korea and was educated at School of Pharmacy, Sunkyunkwan University, where she received her PhD in pharmacology in 2012.

Session Details:

Master protocols in biotech: Design and implementation

2023-12-05, 10:00 AM

View In Agenda
Next speaker
Back
Taegyun Park
Head of R&D, Qratis

2022 Sungkyunkwan University School of Medicine, Ph.D. Clinical Epidemiology

2019 Master of Pharmacy, Sungkyunkwan University Graduate School

1996 Bachelor of Pharmacy, Sungkyunkwan University Graduate School

2023 ~                Head of Research and development in Quratis

2016 ~ 2022(former) Medical Manager in ChungKundang

2001 ~ 2016(former) GSK Medical

Session Details:

Leveraging Real World Evidence/Data for enhanced study design and execution

2023-10-06, 10:30 AM

View In Agenda
Next speaker
Back
Jessica Thongcharen
DIRECTOR, GLOBAL PATIENT SAFETY & EVALUATION – CLINICAL OPERATIONS

A highly skilled pharmacovigilance professional with vast experience in pharmacovigilance operations and regulatory intelligence in the APAC region and internationally. Strong leadership skills in both; project and people management with 18 years of working experience in the healthcare and pharmaceutical industry. Proven ability to set up new Pharmacovigilance (PV) operations, oversee PV compliance, audit, and quality management in the Asia Pacific region with positive track record of successful global PV audit and inspections. A qualified healthcare professional with post-graduate degrees in; Pharmacovigilance and Pharmacoepidemiology (specialized in Risk Identification and Quantification) and Business Administration.

Strong knowledge of relevant Codes of Conduct, aggregate reporting, compliance monitoring, safety databases and hands-on experiences in managing organization M&A as change agents.

Session Details:

PANEL DISCUSSION: Clinical Trials in Asia: Insights and Perspectives ‘Unlocking efficient strategies to manage multiple countries’ regulations for global trials to increase productivity and achieve high quality results from all operation sites

2023-12-06, 11:30 AM

Session Details:

Patient Safety and Evaluation in Clinical Operations: Enhancing Safety and Quality in Clinical Research

2023-12-06, 11:30 AM

View In Agenda
Next speaker
Back
Jandee Kim
Director Clinical Development, ADDPHARMA
Next speaker
Back
Young Su (Bobby) Noh
Director, Head of Clinical Science, Hanmi Pharm

Dr. Noh received his Ph.D. in pharmacy Kyung Hee University and joined Hanmi Pharma in 2009, bringing more than 15 years of experience in clinical research and development. He is responsible for leading clinical program with NMEs or NBEs in multi-therapeutic area: including metabolic diseases and rare disease as well as oncology and hematology. He has lot of experience for collaborating with global big pharma as well as biotech companies.

Previously, he served as an adjunct professor, department of regulatory science for Kyung Hee university and an expert member of external evaluation committee of KDDF.

Session Details:

CASE STUDY Successful Clinical Trial in Oncology; Dose Optimization in Oncology Drug Development

2023-12-05, 2:00 PM

View In Agenda
Next speaker
Back
Sueun Song
Division Head of Clinical Development, Celltrion

EDUCATION :

l  Duksung Women's University, College of Pharmacy

l  Sookmyung Women’s University. Graduate School of Clinical Pharmacy

PROFESSIONAL EXPERIENCE

l  Current: Celltrion, Head of Clinical Development Division

l  Dec 2013 ~ : Celltrion

l  C&R Research

l  PPD Korea

Session Details:

KEY NOTE Choosing the right CRO: Essential considerations for a successful partnership

2023-12-05, 9:00 AM

View In Agenda
Next speaker
Back
KangPyo Lee
Vice President Hanul TL
Next speaker
Back
Seoyeon Hyun
Clinical Development Director, ILIAS Biologics

Seoyeon Hyun is the Head of Clinical Development at ILIAS Biologics. In her role, she is responsible for overseeing the overall clinical development of the company's pipeline and leading global clinical trials for engineered exosome therapeutics.

With over 20 years of experience, she has handled various clinical development tasks, including Phase 1-3 clinical trials for new drug approvals as well as global clinical trials sponsored by multinational pharmaceutical companies. Before joining ILIAS Biologics in September 2021, she held a position overseeing new drug clinical development at a European biotech company, where she led multinational clinical trials in Europe. She has also served as a Clinical Research Manager at MSD and as a clinical project manager for new drug development at Boehringer Ingelheim and SK Chemicals.

Seoyeon Hyun holds a bachelor’s degree from Ewha Womans University College of Pharmacy and a master’s degree in physical pharmacy from Seoul National University.

Next speaker
Back
Jungwon Jung
Manufacturing Manager, HK inno-N
  1. 2001.09~ present: HK inno-N. Manufacturing Team part manager.

; Quality assurance Team / Cell & Gene project Team / Technical development Team / Manufacturing Team

  1. 2000.09~2001.09 : Green Cross Quality control team (Bio Pharm)
  2. 1999.10~2000.09 : LG Chemical Quality assurance team (Quinolones antibiosis)
Next speaker
Back
DaeMan Moon
Director, Team Leader, Global Clinical Supply Management Team, Celltrion

2014.10- Present  Team Leader/Director, Global Supply Chain Management in Celltrion

2012.01-2014.10   Manager, Material Management in Celltrion

Next speaker
Back
Juhee Jeon
PV Manager, PV Team Leader, HANA Pharm.

Ms. Juhee Jeon graduated from Korea University with a Master’s of Science in Medical Microbiology (Virology & Immunology). She has been working in the field of medical information, drug safety in clinical trial, pharmacovigilance and GCP/GVP quality management at pharmaceutical companies and CROs for more than 18 years. Currently, she is responsible for managing drug safety monitoring and pharmacovigilance at Hana Pharm in Korea.

 

Session Details:

Outsourcing of Pharmacovigilance in Korea: An Example and Experience

2023-12-06, 10:00 AM

View In Agenda
Next speaker
Back
HyeJung Yang
Clinical Project Manager, MedPacto

Hyejung Yang is the Clinical Research Manager and Clinical Research Team Lead at MedPacto Inc,. She has almost 12 years of experience in Clinical Research Project management by local pharmaceutical companies.

Next speaker
Back
Yohan Bae
Executive Director
Next speaker
Back
SoYoung Chun
Medical Director, Trial Informatics
Next speaker
Back
Eunsun Lee
Director, TiumBio

Session Details:

Vendor management: Aligning vendors and sponsors for successful trial delivery

2023-12-05, 12:30 PM

View In Agenda
Next speaker
Back
Shin-Il Kim
Chief Scientific Officer, THERABEST

Shin-Il Kim is currently a CSO of Therabest Co., Ltd., a biopharmaceutical company that develops a platform for iPSC-derived immune cells. Prior to joining, he was a R & D director at aceRNA Technologies Co., Ltd., spun off from Center for iPS Cell Research and Application (CiRA) at Kyoto University.

Dr. Kim obtained his Ph.D. in molecular biology from University of Wisconsin-Madison in 2008. He then began his studies of TGF-b signaling in cancer models as a postdoctoral fellow at the University of California-San Francisco. In 2011, he moved to CiRA where Nobel Prize winner Shinya Yamanaka who first succeeded in establishment of iPS cells and became an assistant professor in 2017. He has extensive experience in the fields of genome engineering, iPSC differentiation, and cancer research.

Session Details:

Development of Clinical Grade iPSC-Derived NK cells for Cancer Immunotherapy

2023-12-05, 3:00 PM

View In Agenda
Next speaker
Back
Baek-Jae KIM
Country Manager Korea, IATA

BJ (Baek-Jae) Kim, Ph.D., is the IATA Country Manager Korea, based in Seoul, Republic of Korea. BJ leads a team of 3 (Mr. HT Lee, Ms. Anna Park, and Ms. Hyein Jeon) in the Korea field office work.

Prior to joining IATA in Aug 2019, BJ has about 25 years of aviation experience, including 6 years in United Airlines, 4 years in Air France, and 16 years in Qatar Airways as Airport Services Manager in ICN airport, the Republic of Korea.

BJ holds a Ph.D. and Master of Aviation Business Administration from the Korea Aerospace University (KAU) and a Bachelor's degree in Economics from Hankuk University of Foreign Studies (HUFS) in the Republic of Korea.

BJ is a citizen of the Republic of Korea. He is a Christian and married with 2 children. BJ enjoys hiking, mountain climbing, and other sports in his spare time.

Next speaker
Back
Hyesung Shin
Managing Director, Division Head Clinical Research Development Division, TiumBio

Hyesung Shin, managing director of TiumBio Co., Ltd has worked more than 23 years of experience in clinical trial development and operations.

She had worked during 13 years for global pharmaceutical companies at Eli Lilly, Novo Nordisk and Novartis and 6 years at Abbott for medical devices clinical development and had experienced in Korean Biotech companies of BioPharm Solutions, Aptabio Therapeutics, TiumBio for new drug development and managing phase I/II Clinical Trial.

The works focused on managing clinical trial plan for new drug development, regulatory Filing for FDA/EMEA/MFDS IND, orphan drug Designation, vender management including CRO/Clinical Supplies/CDMO and development of  market strategy.

Next speaker
Back
A Young Kim
R&D division Team leader, Jeil pharm
Next speaker
Back
YOONI KIM
Vice President Clinical Services, Novotech

Head of Clinical Services in Novotech with >22 years’ experience in clinical research industry of CROs, Pharmaceutical company as well as academic research institute. Scientifically qualified as PhD majored in Preventive Medicine in Seoul National University. Experienced in all aspects of clinical research operations management. Broad range to cover Clinical Operations, Study Start-up, Regulatory Affairs, Project Management, Medical Affairs, Pharmacovigilance, Data Management, Business Operations as well as SMO. Joined Novotech in 2016 as head of Asia-Pac region and moved role to global coverage of clinical services in 2021.

Session Details:

The Future of Clinical Trials: Clinical Innovation Solutions Utilizing of Artificial Intelligence (AI)

2023-12-05, 10:30 AM

View In Agenda
Next speaker
Back
Marine du Jardin
APAC Regional Manager & Partnership Lead, N-SIDE

Session Details:

Reducing drug waste – how Technology makes clinical supply more efficient

2023-12-05, 9:30 AM

View In Agenda
Next speaker
Back
Amaury Jeandrain
Vice President of Strategy, N-SIDE

Amaury Jeandrain has a Master’s Degree in Business Engineering with a specialization in supply chain management. After working for a CRO, he joined N-SIDE where he supported the optimization of hundreds of trials from different indications and pharmaceutical companies, providing services ranging from risk-based optimization to clinical trial design and solving drug supply shortage problems. Amaury now leads a group of consultants, focusing on the extension of N-SIDE’s solutions.

Session Details:

Reducing drug waste – how Technology makes clinical supply more efficient

2023-12-05, 9:30 AM

View In Agenda
Next speaker
Back
Sean Smith
Biological Threat Exclusion Coordinator (BTEC), U.S. Customs and Border Protection

Sean Smith is a Biological Threat Exclusion Coordinator (BTEC) for CBP in the Office of Field Operations/ Agriculture Programs and Trade Liaison/ Biological Threat Exclusion. As a BTEC, Mr. Smith is charged with supporting and developing U.S. Customs and Border Protection (CBP) operational capacity and capability in preventing tools of agro/bio-terrorism from entering the U.S.  Mr. Smith has more than 17 years of public service with CBP, and has worked in a variety of environments, including on the southern land border, maritime, air passenger, and cargo locations.  He has also been able to assist in several past domestic and international CBP disaster recovery operations.

Next speaker
Back
Gina Reneau
Biological Threat Exclusion Coordinator, U.S. Customs & Border Protection

Gina Reneau is a Biological Threat Exclusion Coordinator (BTEC) for U.S. Customs and Border Protection (CBP) in the Office of Field Operations

Agriculture Programs and Trade Liaison/ Biological Threat Exclusion.  As a BTEC, Ms. Reneau is charged with supporting and developing CBP operational capacity and capability in preventing tools of agro/bio-terrorism from entering the U.S.  Ms. Reneau has more than 27 years of public service with CBP, and has worked in a variety of environments, including in air passenger, cargo, maritime, and express consignment locations.

Next speaker
Back
Daniela Caiazza
Senior Director Clinical Services and Innovation, Novotech

Session Details:

The Future of Clinical Trials: Clinical Innovation Solutions Utilizing of Artificial Intelligence (AI)

2023-12-05, 10:30 AM

View In Agenda
Next speaker

Plan Your Visit

Venue

Arena International Events Group “(Arena”) is aware of numerous third party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings and events attendee lists. For the avoidance of doubt, Arena will only share attendee lists with carefully selected third party partners for event registration purposes. Whilst Arena International Events Group pursues third party agencies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group.

Sponsors

Select a sponsor to learn more

Featured Sponsor

Session Sponsor

Exhibitors

Why partner?

 

Contact us to become a partner

Partnership Opportunities

We work with you to design a bespoke package to meet your business needs, where you could:

  • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
  • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
    Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
  • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

Event reach

  • 150+ attendees each year
  • 80% attendees C-suite level

 

Take a look at our current sponsors

Media Centre

Media Partners

Become A Media Partner

Enquiry

Contact Us

SPONSORSHIP ENQUIRIES

Nicholas McCudden

Head of OCT Events

+61 280 978 126

SPEAKER ENQUIRIES

Ranhee Yoo

Conference Producer

+44 207947 2793

MARKETING ENQUIRIES

Haida Amirzadah

Marketing Manager

DELEGATE ENQUIRIES

Sunny Saikia

VIP Delegate Manager

Sponsorship Enquiries

To enquire about sponsorship opportunities for the conference, please contact:

Nicholas McCudden

Head of OCT Events


+61 280 978 126

Speaker Enquiries

To enquire about speaking opportunities for the conference, please contact:

Ranhee Yoo

Conference Producer


+44 207947 2793